CD274 and non-small cell lung carcinoma: Among others, the PACIFIC trial’s concurrent treatment with the anti-PD-L1 antibody durvalumab to curatively intended chemoradiotherapy in stage III NSCLC patients provided proof-of-concept for improvement of survival outcomes by molecularly targeted pharmacological interventions in conjunction with radiotherapy [11–13].